Zentalis Pharmaceuticals (ZNTL) Stock Forecast, Price Target & Predictions
ZNTL Stock Forecast
Zentalis Pharmaceuticals stock forecast is as follows: an average price target of $21.86 (represents a 486.06% upside from ZNTL’s last price of $3.73) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
ZNTL Price Target
The average price target for Zentalis Pharmaceuticals (ZNTL) is $21.86 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $55.00 to $4.00. This represents a potential 486.06% upside from ZNTL's last price of $3.73.
ZNTL Analyst Ratings
According to 10 Wall Street analysts, Zentalis Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ZNTL stock is 0 'Strong Buy' (0.00%), 5 'Buy' (50.00%), 5 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Zentalis Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 18, 2024 | Akash Tewari | Jefferies | $6.00 | $4.30 | 39.37% | 60.86% |
| Jun 18, 2024 | Matthew Harrison | Morgan Stanley | $8.00 | $4.14 | 93.24% | 114.48% |
| Jun 18, 2024 | Bradley Canino | Stifel Nicolaus | $10.00 | $5.39 | 85.53% | 168.10% |
| Jun 18, 2024 | Robert Driscoll | Wedbush | $4.00 | $5.70 | -29.82% | 7.24% |
| May 07, 2024 | Bradley Canino | Stifel Nicolaus | $32.00 | $12.43 | 157.44% | 757.91% |
| Nov 14, 2022 | - | Wedbush | $32.00 | $22.56 | 41.84% | 757.91% |
| Nov 11, 2022 | - | Morgan Stanley | $55.00 | $20.90 | 163.16% | 1374.53% |
| Nov 11, 2022 | - | Guggenheim | $28.00 | $21.35 | 31.15% | 650.67% |
| Aug 10, 2022 | - | Leerink Partners | $42.00 | $30.41 | 38.11% | 1026.01% |
| Aug 10, 2022 | - | H.C. Wainwright | $55.00 | $30.41 | 80.86% | 1374.53% |
The latest Zentalis Pharmaceuticals stock forecast, released on Jun 18, 2024 by Akash Tewari from Jefferies, set a price target of $6.00, which represents a 39.37% increase from the stock price at the time of the forecast ($4.30), and a 60.86% increase from ZNTL last price ($3.73).
Zentalis Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 5 |
| Avg Price Target | - | - | $12.00 |
| Last Closing Price | $3.73 | $3.73 | $3.73 |
| Upside/Downside | -100.00% | -100.00% | 221.72% |
In the current month, the average price target of Zentalis Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Zentalis Pharmaceuticals's last price of $3.73. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 16, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 12, 2024 | Wedbush | Hold | Neutral | Upgrade |
| Jun 20, 2024 | UBS | - | Neutral | Downgrade |
| Jun 18, 2024 | Jefferies | - | Hold | Downgrade |
| Jun 18, 2024 | Morgan Stanley | Equal-Weight | Hold | Downgrade |
| Jun 18, 2024 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| Jun 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 18, 2024 | Wedbush | Underperform | Hold | Downgrade |
| Jun 18, 2024 | Wedbush | Outperform | Underperform | Downgrade |
Zentalis Pharmaceuticals's last stock rating was published by Cowen & Co. on Sep 16, 2024. The company gave ZNTL a "Buy" rating, the same as its previous rate.
Zentalis Pharmaceuticals Financial Forecast
Zentalis Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | $15.00M | $100.00K |
| High Forecast | - | - | - | - | - | - | - | $15.00M | $100.00K |
| Low Forecast | - | - | - | - | - | - | - | $15.00M | $100.00K |
| # Analysts | - | - | - | - | - | - | - | 4 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - |
Zentalis Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ZNTL's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Zentalis Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 4 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | $-15.92M |
| Avg Forecast | - | - | - | - | - | - | - | - | $-31.13M |
| High Forecast | - | - | - | - | - | - | - | - | $-24.91M |
| Low Forecast | - | - | - | - | - | - | - | - | $-37.36M |
| Surprise % | - | - | - | - | - | - | - | - | 0.51% |
undefined analysts predict ZNTL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Zentalis Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Zentalis Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 4 | 2 |
| Net Income | - | - | - | - | - | - | - | - | $-16.13M |
| Avg Forecast | $-67.67M | $-65.51M | $-69.59M | $-68.00M | $-69.11M | $-64.62M | $-59.73M | $-54.51M | $-30.69M |
| High Forecast | $-67.67M | $-65.51M | $-69.59M | $-68.00M | $-69.11M | $-60.41M | $-59.73M | $-54.51M | $-24.55M |
| Low Forecast | $-67.67M | $-65.51M | $-69.59M | $-68.00M | $-69.11M | $-69.54M | $-59.73M | $-54.51M | $-36.82M |
| Surprise % | - | - | - | - | - | - | - | - | 0.53% |
Zentalis Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ZNTL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Zentalis Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 4 | 2 |
| SG&A | - | - | - | - | - | - | - | - | $3.14M |
| Avg Forecast | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - |
Zentalis Pharmaceuticals's average Quarter SG&A projection for Mar 24 is -, based on 4 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ZNTL last annual SG&A of $3.14M (Mar 20).
Zentalis Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 4 | 2 |
| EPS | - | - | - | - | - | - | - | - | $-0.49 |
| Avg Forecast | $-0.95 | $-0.92 | $-0.98 | $-0.96 | $-0.97 | $-0.91 | $-0.84 | $-0.77 | $-0.70 |
| High Forecast | $-0.95 | $-0.92 | $-0.98 | $-0.96 | $-0.97 | $-0.85 | $-0.84 | $-0.77 | $-0.70 |
| Low Forecast | $-0.95 | $-0.92 | $-0.98 | $-0.96 | $-0.97 | $-0.98 | $-0.84 | $-0.77 | $-0.70 |
| Surprise % | - | - | - | - | - | - | - | - | 0.70% |
According to undefined Wall Street analysts, Zentalis Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ZNTL previous annual EPS of $NaN (undefined).
Zentalis Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals | $3.73 | $21.86 | 486.06% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| ITOS | iTeos Therapeutics | $8.97 | $37.67 | 319.96% | Buy |
| INZY | Inozyme Pharma | $4.42 | $14.67 | 231.90% | Buy |
| SANA | Sana Bio | $3.76 | $12.00 | 219.15% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
| ERAS | Erasca | $2.87 | $7.00 | 143.90% | Buy |
| OLMA | Olema Pharmaceuticals | $11.86 | $28.50 | 140.30% | Buy |
| CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
| ANNX | Annexon | $7.09 | $14.00 | 97.46% | Buy |
| SNDX | Syndax Pharmaceuticals | $18.94 | $36.11 | 90.65% | Buy |
| DSGN | Design Therapeutics | $5.32 | $9.67 | 81.77% | Buy |
| BPMC | Blueprint Medicines | $91.88 | $109.71 | 19.41% | Buy |
| KYMR | Kymera Therapeutics | $47.07 | $51.50 | 9.41% | Buy |
| PTGX | Protagonist Therapeutics | $46.76 | $50.00 | 6.93% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $55.87 | $58.57 | 4.83% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
ZNTL Forecast FAQ
Is Zentalis Pharmaceuticals a good buy?
Yes, according to 10 Wall Street analysts, Zentalis Pharmaceuticals (ZNTL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 50.00% of ZNTL's total ratings.
What is ZNTL's price target?
Zentalis Pharmaceuticals (ZNTL) average price target is $21.86 with a range of $4 to $55, implying a 486.06% from its last price of $3.73. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Zentalis Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for ZNTL stock, the company can go up by 486.06% (from the last price of $3.73 to the average price target of $21.86), up by 1374.53% based on the highest stock price target, and up by 7.24% based on the lowest stock price target.
Can Zentalis Pharmaceuticals stock reach $6?
ZNTL's average twelve months analyst stock price target of $21.86 supports the claim that Zentalis Pharmaceuticals can reach $6 in the near future.
What are Zentalis Pharmaceuticals's analysts' financial forecasts?
Zentalis Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $15M (high $15M, low $15M), average EBITDA is $0 (high $0, low $0), average net income is $-248M (high $-244M, low $-253M), average SG&A $0 (high $0, low $0), and average EPS is $-3.491 (high $-3.431, low $-3.56). ZNTL's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-271M (high $-271M, low $-271M), average SG&A $0 (high $0, low $0), and average EPS is $-3.811 (high $-3.811, low $-3.811).